Highlights embody: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology firm
SOPHiA GENETICS’ next-generation resolution CarePath, fueled by present actual world observational knowledge, was previewed for attendees
BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software program firm within the healthcare house, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.
The occasion, hosted by the CEO and Co-Founder Dr. Jurgi Camblong and members of the chief management crew, offered a roadmap of the Company’s long-term imaginative and prescient and highlighted new business alternatives and partnerships. One takeaway from the occasion was SOPHiA GENETICS’ acceleration into the Biopharma house, which opens the door for brand new alternatives for market progress. The viewers additionally heard how the Company’s strategic business mannequin permits for it to proceed to present sturdy depth within the scientific house.
“A key theme throughout the day was how we innovate; how SOPHiA GENETICS, from its inception, has identified opportunities in the healthcare industry for innovation and acceleration of data sharing to advance medicine, research and patient care,” stated Jurgi Camblong, CEO and Co-Founder, SOPHiA GENETICS. “Our vision is made possible by the strong foundation our company has been built on, as well as the strategic relationships we have formed to further our mission of democratizing data-driven medicine.”
New Collaboration with One of the Top-Ranked Cancer Centers within the United States
SOPHiA GENETICS just lately introduced a memorandum of understanding to enter right into a collaboration with Memorial Sloan Kettering Cancer Center (“MSK”). Once executed, the collaboration agreements will mix the facility of SOPHiA GENETICS’ giant, international community and deep experience in predictive algorithms with MSK’s scientific experience in most cancers genomics. The collaboration agreements can even enable SOPHiA GENETICS’ international community of healthcare suppliers entry to MSK’s proprietary tumor sequencing exams comparable to MSK-IMPACT®, for analyzing tumors. Additionally, the collaboration agreements will mix MSK’s wealthy precision oncology knowledge with the SOPHiA CarePath™ module to allow the acceleration of actionable insights from knowledge to enhance affected person outcomes.
“Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform,” stated Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.
Enabling Biotech Developing Novel Cancer Therapies Targeting Oncogene Amplification
SOPHiA GENETICS introduced a partnership with Boundless Bio, a next-generation precision oncology firm creating modern therapeutics directed in opposition to extrachromosomal DNA (ecDNA) in oncogene amplified cancers.
It has been effectively established that sufferers with oncogene amplification typically don’t profit from customary of care most cancers remedies, and in contrast to different types of oncogenic gene alterations, oncogene amplification regularly happens on ecDNA. ecDNA are round items of nuclear DNA which can be distinct from regular chromosomes and are the first website for top copy quantity amplification in most cancers. Boundless Bio is creating the primary ecDNA-directed therapies (ecDTx) together with a precision diagnostic technique known as ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a affected person’s routine tumor sequencing knowledge.
The partnership between Boundless Bio and SOPHiA GENETICS will additional develop ECHO to be used in ecDTx scientific trials.
SOPHiA GENETICS’ distinctive means to harmonize knowledge derived from various genomic devices and deploy as a strong, standardized resolution permits a brand new mannequin for scientific trial testing. This decentralized, international genomic resolution mixed with Boundless Bio’s ecDTx drug growth capabilities goals to unlock worth by breaking the obstacles inherent to the normal central lab method; optimizing affected person choice and scientific trial design; and enabling a world collective community of main hospitals and educational facilities to successfully ship new remedy choices to sufferers with oncogene amplified cancers.
“We are pleased to partner with SOPHiA GENETICS for the development of Boundless Bio’s ecDNA detection algorithm, ECHO, into a clinical trial device,” stated Peter Krein, Ph.D., Vice President of Precision Medicine at Boundless Bio. “The ability to identify patients with ecDNA driven tumors is critical to our mission in addressing this area of high unmet medical need. SOPHiA GENETICS’ unique expertise in developing cloud based IVD NGS software algorithms makes them an ideal partner to develop ECHO into an investigational device.”
DEEP-Lung-IV Multimodal Clinical Study Fuels New SOPHiA Carepath Platform
In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study with the objective of aggregating real-world multimodal (genomic, scientific, organic and radiomic) knowledge for sufferers with metastatic non-small cell lung most cancers. The examine has garnered curiosity from top-tier facilities globally, with a robust affected person recruitment pattern; to-date, almost 900 sufferers throughout 23 websites have been enrolled within the examine. As sufferers have been adopted alongside the affected person journey, knowledge units have been collected and analyzed by SOPHiA GENETICS’ machine studying algorithm to predict how the sufferers will reply to immunotherapy and why.
These sturdy and rising affected person knowledge will inform SOPHiA GENETICS’ synthetic intelligence and machine studying that can gasoline the forthcoming SOPHiA CarePath™ module, a brand new product that might be launched on the SOPHiA DDM™ Platform and goals to be the car healthcare practitioners can use to leverage the real-world, real-time insights obtained from this examine. The SOPHiA CarePath™ module will present the next advantages:
- Visualizing knowledge type a single affected person in a holistic method (genomic, scientific, organic and radiomic)
- Allow suppliers to cohort sufferers within the context of comparable sufferers from different establishments
Alongside these bulletins, a full recording of the occasion is on the market on the Investor Relations web page of the corporate’s web site.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software program firm devoted to establishing the apply of data-driven drugs as the usual of care and for all times sciences analysis. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform able to analyzing knowledge and producing insights from advanced multimodal knowledge units and completely different diagnostic modalities. The SOPHiA DDM™ Platform and associated options, services are presently utilized by a broad community of hospital, laboratory, and biopharma establishments globally. For extra data, go to SOPHiAGENETICS.COM, or join on Twitter, LinkedIn, Facebook, and Instagram. Where others see knowledge, we see solutions
SOPHiA GENETICS merchandise are for Research Use Only and never to be used in diagnostic procedures, until specified in any other case. The data on this press launch is about merchandise that will or is probably not obtainable in several nations and, if relevant, could or could not have obtained approval or market clearance by a governmental regulatory physique for various indications to be used. Please contact email@example.com to receive the suitable product data to your nation of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press launch accommodates statements that represent forward-looking statements. All statements aside from statements of historic info contained on this press launch, together with statements relating to our future outcomes of operations and monetary place, business technique, merchandise and expertise, in addition to plans and goals of administration for future operations, are forward-looking statements. Forward-looking statements are primarily based on our administration’s beliefs and assumptions and on data presently obtainable to our administration. Such statements are topic to dangers and uncertainties, and precise outcomes could differ materially from these expressed or implied within the forward-looking statements due to varied components, together with these described in our filings with the U.S. Securities and Exchange Commission. No assurance might be on condition that such future outcomes might be achieved. Such forward-looking statements contained on this press launch converse solely as of the date hereof. We expressly disclaim any obligation or endeavor to replace these forward-looking statements contained on this press launch to mirror any change in our expectations or any change in occasions, situations, or circumstances on which such statements are primarily based, until required to achieve this by relevant regulation. No representations or warranties (expressed or implied) are made concerning the accuracy of any such forward-looking statements.
Senior Manager, Media & Communications
Head of Investor Relations